AOI excels in hereditary breast cancer care
Source: Chronicle News Service

Imphal, December 28 2024: American Oncology Institute (AOI) in Imphal, has successfully treated a 36 -year old woman diagnosed with hereditary breast cancer, showcasing its expertise in advanced cancer care and targeted therapies.

The patient, unmarried, initially presented with a tumor in her right breast, along with metastasis (spread) to her armpit and lungs, as confirmed by PET-CT imaging, informed a release issued by Institute sales and marketing head Gopen Tongbram.

According to Gopen, the patient was diagnosed with triple-negative breast cancer, a form of the disease known for its aggressive nature and limited treatment options.

She underwent 12 cycles of palliative chemotherapy, achieving a complete response initially.

The patient continued with maintenance therapy, but after 12 cycles, her PET-CT scan revealed disease progression in the breast and armpit.

Recognising the potential hereditary nature of her condition, doctors conducted a blood test.

The results confirmed a mutation, which increases the risk of hereditary breast cancer.

Deciding the next step of treatment, AOI Imphal medical oncologist Dr Shibashish Bhattacharyya explained "Once we identified the mutation, we introduced a second line of chemotherapy, and a targeted oral therapy designed specifically to address the genetic defect.

This combination blocks the effects of the mutation and helps the body repair DNA more effectively" .

After four months of this advanced treatment, the patient achieved complete metabolic response, with no signs of cancer detected on her scan.

"The mutation in the BRCA gene affects DNA repair mechanisms, which can lead to cancer.

However, targeted therapies designed for BRCA mutations have shown remarkable results, offering new hope to patients with hereditary breast cancer," Dr Bhattacharyya added.

CTSI-South Asia CEO Harish Trivedi emphasised the significance of personalised cancer care stating "This case highlights the importance of genetic testing and precision medicine in cancer treatment.

At AOI, we strive to provide world-class Cancer Care tailored to the individual needs of each patient.

The success of this treatment reflects our commitment to leveraging the latest medical advancements for better outcomes".

AOI Imphal regional COO Dr Amit Dhawan noted, "Hereditary breast cancer cases require a multidisciplinary and highly specialised approach.

AOI's ability to combine advanced diagnostics, cutting-edge therapies, and expert care ensures that patients like this can have a second chance at life" .

Hereditary breast cancer accounts for approximately 5-10 per cent of all breast cancer cases and is often linked to BRCA1 and BRCA2 gene mutations.

Women with these mutations have a significantly higher risk of developing breast and ovarian cancer.

Targeted therapies, such as PARP inhibitors, are revolutionising the treatment landscape, offering patients more effective and less invasive treatment options.

American Oncology Institute in Imphal continues to lead the way in offering comprehensive Cancer Care, combining the latest technology with the expertise of seasoned oncologists to deliver exceptional outcomes for patients, Gopen conveyed.

Comment